Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 24 | 2024 | 2508 | 2.770 |
Why?
|
| Proteogenomics | 6 | 2023 | 67 | 2.150 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2024 | 234 | 1.330 |
Why?
|
| Cyclin-Dependent Kinase 6 | 3 | 2024 | 41 | 1.030 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2024 | 722 | 0.810 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 13 | 0.700 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2024 | 532 | 0.640 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2020 | 120 | 0.640 |
Why?
|
| DNA-(Apurinic or Apyrimidinic Site) Lyase | 1 | 2018 | 12 | 0.610 |
Why?
|
| DNA Glycosylases | 1 | 2018 | 32 | 0.600 |
Why?
|
| Antineoplastic Agents, Hormonal | 4 | 2021 | 256 | 0.600 |
Why?
|
| Antigens, CD | 1 | 2020 | 421 | 0.600 |
Why?
|
| Endonucleases | 1 | 2018 | 54 | 0.590 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 324 | 0.540 |
Why?
|
| Cyclin-Dependent Kinase 4 | 3 | 2024 | 57 | 0.530 |
Why?
|
| Proteomics | 3 | 2022 | 491 | 0.490 |
Why?
|
| Proteome | 4 | 2023 | 241 | 0.470 |
Why?
|
| Receptors, Estrogen | 8 | 2024 | 793 | 0.470 |
Why?
|
| Cell Cycle Proteins | 1 | 2018 | 645 | 0.440 |
Why?
|
| Neoadjuvant Therapy | 4 | 2024 | 326 | 0.440 |
Why?
|
| Estrogen Receptor alpha | 4 | 2023 | 467 | 0.440 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 2055 | 0.420 |
Why?
|
| Aromatase Inhibitors | 4 | 2022 | 77 | 0.400 |
Why?
|
| Mycobacterium tuberculosis | 3 | 2012 | 378 | 0.390 |
Why?
|
| Drug Delivery Systems | 2 | 2012 | 185 | 0.390 |
Why?
|
| Protein Folding | 1 | 2011 | 218 | 0.360 |
Why?
|
| Bacterial Proteins | 3 | 2012 | 885 | 0.350 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2009 | 157 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1239 | 0.290 |
Why?
|
| Receptor, ErbB-2 | 5 | 2024 | 515 | 0.290 |
Why?
|
| Neurofibromin 1 | 3 | 2023 | 42 | 0.260 |
Why?
|
| Proteins | 1 | 2011 | 1044 | 0.260 |
Why?
|
| Female | 24 | 2024 | 66305 | 0.260 |
Why?
|
| Humans | 32 | 2024 | 124405 | 0.250 |
Why?
|
| Carboplatin | 2 | 2022 | 76 | 0.250 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2022 | 83 | 0.240 |
Why?
|
| Computational Biology | 1 | 2009 | 820 | 0.230 |
Why?
|
| Gene Expression Profiling | 3 | 2020 | 1695 | 0.230 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 1674 | 0.230 |
Why?
|
| Mutation | 6 | 2023 | 5809 | 0.220 |
Why?
|
| MCF-7 Cells | 3 | 2020 | 222 | 0.220 |
Why?
|
| Prognosis | 6 | 2023 | 4554 | 0.220 |
Why?
|
| Tissue Array Analysis | 2 | 2020 | 137 | 0.210 |
Why?
|
| X-ray Repair Cross Complementing Protein 1 | 1 | 2022 | 21 | 0.210 |
Why?
|
| Circulating Tumor DNA | 1 | 2022 | 33 | 0.200 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2022 | 63 | 0.200 |
Why?
|
| Mass Spectrometry | 1 | 2023 | 331 | 0.190 |
Why?
|
| Quinolines | 1 | 2022 | 96 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2024 | 1460 | 0.170 |
Why?
|
| Tamoxifen | 2 | 2020 | 363 | 0.170 |
Why?
|
| Multienzyme Complexes | 2 | 2011 | 90 | 0.170 |
Why?
|
| Up-Regulation | 2 | 2020 | 862 | 0.170 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 75 | 0.170 |
Why?
|
| Gene Regulatory Networks | 2 | 2020 | 355 | 0.170 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2019 | 9 | 0.170 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2019 | 40 | 0.170 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2019 | 54 | 0.170 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2021 | 212 | 0.170 |
Why?
|
| Trastuzumab | 1 | 2020 | 134 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2020 | 145 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 109 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1899 | 0.160 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2304 | 0.160 |
Why?
|
| Ki-67 Antigen | 3 | 2024 | 113 | 0.160 |
Why?
|
| Protein Kinases | 2 | 2020 | 334 | 0.160 |
Why?
|
| DNA Repair | 2 | 2020 | 589 | 0.150 |
Why?
|
| Antitubercular Agents | 2 | 2011 | 247 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 353 | 0.150 |
Why?
|
| Gene Fusion | 1 | 2018 | 55 | 0.150 |
Why?
|
| Interferon-gamma | 1 | 2020 | 502 | 0.150 |
Why?
|
| Heterografts | 1 | 2018 | 177 | 0.140 |
Why?
|
| MutL Proteins | 1 | 2017 | 19 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 334 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2017 | 36 | 0.140 |
Why?
|
| Transcriptome | 2 | 2021 | 937 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2021 | 288 | 0.140 |
Why?
|
| Gene Amplification | 1 | 2016 | 228 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2024 | 887 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2020 | 4535 | 0.120 |
Why?
|
| Genomic Instability | 1 | 2016 | 229 | 0.120 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 943 | 0.110 |
Why?
|
| Protein Interaction Mapping | 2 | 2012 | 84 | 0.100 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 3342 | 0.100 |
Why?
|
| Crowdsourcing | 1 | 2012 | 10 | 0.100 |
Why?
|
| Subcellular Fractions | 1 | 2011 | 98 | 0.100 |
Why?
|
| Protein Structure, Quaternary | 1 | 2011 | 98 | 0.090 |
Why?
|
| Middle Aged | 6 | 2024 | 26460 | 0.090 |
Why?
|
| Genome, Bacterial | 1 | 2012 | 184 | 0.090 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 238 | 0.090 |
Why?
|
| Postmenopause | 2 | 2024 | 123 | 0.090 |
Why?
|
| Mice | 4 | 2024 | 17728 | 0.090 |
Why?
|
| Animals | 6 | 2024 | 34145 | 0.090 |
Why?
|
| Biomarkers | 1 | 2019 | 2980 | 0.090 |
Why?
|
| Protein Transport | 1 | 2011 | 368 | 0.090 |
Why?
|
| Disease | 1 | 2011 | 129 | 0.090 |
Why?
|
| Mice, Nude | 2 | 2021 | 710 | 0.080 |
Why?
|
| Amino Acids | 1 | 2011 | 663 | 0.080 |
Why?
|
| Membrane Proteins | 2 | 2022 | 1529 | 0.080 |
Why?
|
| GTP-Binding Proteins | 1 | 2009 | 171 | 0.080 |
Why?
|
| Macrophages | 1 | 2012 | 618 | 0.080 |
Why?
|
| Cell Nucleus | 2 | 2020 | 677 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2023 | 2824 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2009 | 643 | 0.070 |
Why?
|
| Apoptosis | 2 | 2024 | 1790 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2020 | 548 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2020 | 4734 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1127 | 0.060 |
Why?
|
| Immunotherapy | 2 | 2021 | 662 | 0.060 |
Why?
|
| Genomics | 3 | 2020 | 1490 | 0.060 |
Why?
|
| DNA Damage | 2 | 2020 | 515 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2019 | 1482 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 211 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 50 | 0.050 |
Why?
|
| Nitriles | 1 | 2024 | 146 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 85 | 0.050 |
Why?
|
| Purines | 1 | 2023 | 110 | 0.050 |
Why?
|
| Triazoles | 1 | 2024 | 139 | 0.050 |
Why?
|
| Pyridines | 1 | 2024 | 229 | 0.050 |
Why?
|
| Piperazines | 1 | 2024 | 233 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2022 | 144 | 0.050 |
Why?
|
| Quinazolines | 1 | 2022 | 176 | 0.050 |
Why?
|
| APOBEC Deaminases | 1 | 2020 | 6 | 0.050 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2022 | 764 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2022 | 606 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 78 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2023 | 315 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 88 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2020 | 30 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 37 | 0.040 |
Why?
|
| British Columbia | 1 | 2019 | 8 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 1064 | 0.040 |
Why?
|
| Aged | 3 | 2024 | 19479 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 200 | 0.040 |
Why?
|
| Estrogen Antagonists | 1 | 2020 | 103 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6470 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2020 | 347 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2021 | 286 | 0.040 |
Why?
|
| Adult | 4 | 2021 | 29397 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 136 | 0.040 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2019 | 37 | 0.040 |
Why?
|
| Brazil | 1 | 2019 | 123 | 0.040 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2018 | 7 | 0.040 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2018 | 7 | 0.040 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Mice, SCID | 1 | 2020 | 571 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 266 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 217 | 0.040 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2018 | 73 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2022 | 719 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2023 | 1024 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2020 | 473 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 701 | 0.040 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 426 | 0.040 |
Why?
|
| Metabolomics | 1 | 2020 | 420 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 6 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 374 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2020 | 1625 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2023 | 12287 | 0.030 |
Why?
|
| Survival Rate | 1 | 2021 | 2020 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2018 | 340 | 0.030 |
Why?
|
| Disease Progression | 1 | 2022 | 2042 | 0.030 |
Why?
|
| Transfection | 1 | 2018 | 1069 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2019 | 1015 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1404 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2019 | 879 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2017 | 616 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1612 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2023 | 4355 | 0.030 |
Why?
|
| Quantitative Structure-Activity Relationship | 1 | 2011 | 15 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2018 | 3268 | 0.020 |
Why?
|
| Host-Pathogen Interactions | 1 | 2012 | 254 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2011 | 172 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 2699 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 8979 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 3873 | 0.020 |
Why?
|
| Male | 1 | 2021 | 61028 | 0.010 |
Why?
|